Apollo Therapeutics will inject capital and expertise into pipeline of potentially lifesaving medicines through an agreement with the University of Oxford. The collaboration highlights a shared strategic intent to develop new therapeutics based on breakthroughs in biology and basic medical research at the University of Oxford.
Dr Chris Ballance, co-founder and CEO of quantum computing spinout Oxford Ionics talks about the commercial challenges, successful funding rounds, and future collaborations.
Amber Therapeutics successfully closed Series A funding of $100 million (£80 million) from leading healthcare and technology investors in the US and UK.
Oxford University Innovation recently hosted two landmark events that brought together global investors, leading industry experts and innovative spinouts, showcasing the vibrant ecosystem of collaboration and cutting-edge technology at Oxford.
An Oxford University spinout which supports accurate AI applications using Knowledge & Reasoning has been bought by Samsung Electronics.
Discover why Clinical Outcome Assessments (COAs) are vital in clinical trials for measuring patient outcomes and ensuring reliable data for regulatory approval and improved patient care.
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at University of Oxford.
The third year of the Jamie Awards featured ideas such as cleaner hydrogen use in chemical production, an agrochemical for improving crop resilience to floods, advancements in materials for safer and more efficient batteries, and the development of new medical treatments using 3D printing.
Oxford University Innovation (OUI) will welcome more than 50 investors today for the first ever Deep Tech focused showcase day in Oxford to connect them with spinout companies seeking investment and partnership.
